A study to identify novel biomarkers associated with multiple myeloma
Open Access
- 16 November 2023
- journal article
- review article
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 22 (5) , 134-144
Abstract
Background. multiple myeloma (mm) is a plasma cell cancer that affects white blood cells. plasma cells from the bone marrow grow abnormally, as a consequence of which patients have high amounts of monoclonal immunoglobulin in their blood and urine, poor renal function, and recurring infections due to this condition. osteolytic bone lesions and immunodeficiency also impact multiple myeloma patients’ longevity and quality of life. The disease accounts for 13 % of all hematological malignancies worldwide, making it the second most common blood cancer.Material and Methods. The studies investigating mm biomarkers from 2000 to 2021 are collected from various databases. “multiple myeloma”, “biomarkers”, “genetic markers”, “prognostic markers”, “epidemiology of multiple myeloma”, and “risk factors for multiple myeloma” are the key phrases utilized to gather the articles.Results. The scientific and medical research progressed into mm, and the number of cases increased over time and continues to rise, prompting researchers and clinicians to discover new consequences of the disease and new markers for prognosis, diagnosis, detection, and treatment of cancer in the earliest stages. Prognostic and predictive signs for illness recurrence and response to medication may be detected adequately by innovative potential biomarkers, which are more accurate than current approaches.Conclusion. treatment for multiple myeloma includes a variety of chemotherapeutic medicines, including immune modulators and proteasome inhibitors; however, most patients still experience recurrence after completing treatment. There have been numerous novel techniques for managing multiple myeloma, and this review summarises the most commonly used and the new ones that have appeared in the previously published articles.Keywords
This publication has 75 references indexed in Scilit:
- Publication of Tumor Marker Research Results: The Necessity for Complete and Transparent ReportingJournal of Clinical Oncology, 2012
- The genetic architecture of multiple myelomaNature Reviews Cancer, 2012
- Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2Blood, 2011
- Initial genome sequencing and analysis of multiple myelomaNature, 2011
- Racial disparities in incidence and outcome in multiple myeloma: a population-based studyBlood, 2010
- Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myelomaHaematologica, 2010
- Bone marrow microenvironment and the identification of new targets for myeloma therapyLeukemia, 2008
- Tumour vascularization: sprouting angiogenesis and beyondCancer and Metastasis Reviews, 2007
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1Blood, 2006
- Angiogenesis in life, disease and medicineNature, 2005